Floatz logo

2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID

Cholestasis

Assistance Publique - Hôpitaux de ParisSmall moleculePhase 3Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

8 Active assets in the Cholestasis cohort.

Asset / SponsorPhaseRating
Linerixibat
GlaxoSmithKline
Phase 3BB
URSODEOXYCHOLIC ACID
Assistance Publique - Hôpitaux de Paris
Phase 3BB
lum001
Mirum Pharmaceuticals, Inc.
Phase 3BB
CYCLOHEXANEACETIC ACID, 1-(AMINOMETHYL)-
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Phase 3B
Tauroursodeoxycholic
Beijing Trendful Kangjian Medical Information Consulting Limited Company
Phase 3B

View all 24 →

Same molecule, other indications

2-(P-(2-(P-CHLOROBENZAMIDO)ETHYL)PHENOXY)-2-METHYLPROPIONIC ACID is also rated in:

HypercholesterolemiaDormant
BB
Indicative ·
68 / 100
View asset →
primary biliary cholangitisDormant
BB
Indicative ·
67 / 100
View asset →
acute coronary syndromeDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →